FIELD: medicine; sexual pathology.
SUBSTANCE: prevention of cardiovascular by-effects induced by introduction of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction in men is ensured with introduction of one preparation from the specified group: Sildenafil citrate dosed 25-100 mg, or Vardenafil hydrochloride dosed 5-20 mg, or Tadalafil dosed 20 mg, combined with introduction of De-Nol dosed 1 tablet.
EFFECT: improved microcirculation due to higher synthesis of endogenous prostaglandins and prevented cardiovascular by-effects induced by introduction of specified preparations, improved erection in present category of patients.
1 ex
